1. Home
  2. GBIO vs DRIO Comparison

GBIO vs DRIO Comparison

Compare GBIO & DRIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • DRIO
  • Stock Information
  • Founded
  • GBIO 2016
  • DRIO 2011
  • Country
  • GBIO United States
  • DRIO United States
  • Employees
  • GBIO N/A
  • DRIO N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • DRIO Medical/Dental Instruments
  • Sector
  • GBIO Health Care
  • DRIO Health Care
  • Exchange
  • GBIO Nasdaq
  • DRIO Nasdaq
  • Market Cap
  • GBIO 23.2M
  • DRIO 23.9M
  • IPO Year
  • GBIO 2020
  • DRIO N/A
  • Fundamental
  • Price
  • GBIO $0.39
  • DRIO $0.75
  • Analyst Decision
  • GBIO Strong Buy
  • DRIO Strong Buy
  • Analyst Count
  • GBIO 4
  • DRIO 1
  • Target Price
  • GBIO $7.33
  • DRIO $2.00
  • AVG Volume (30 Days)
  • GBIO 559.5K
  • DRIO 318.8K
  • Earning Date
  • GBIO 05-12-2025
  • DRIO 05-14-2025
  • Dividend Yield
  • GBIO N/A
  • DRIO N/A
  • EPS Growth
  • GBIO N/A
  • DRIO N/A
  • EPS
  • GBIO N/A
  • DRIO N/A
  • Revenue
  • GBIO $19,892,000.00
  • DRIO $27,040,000.00
  • Revenue This Year
  • GBIO N/A
  • DRIO $22.41
  • Revenue Next Year
  • GBIO $10.90
  • DRIO $19.97
  • P/E Ratio
  • GBIO N/A
  • DRIO N/A
  • Revenue Growth
  • GBIO 236.92
  • DRIO 32.86
  • 52 Week Low
  • GBIO $0.32
  • DRIO $0.50
  • 52 Week High
  • GBIO $4.34
  • DRIO $1.93
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 43.58
  • DRIO 61.37
  • Support Level
  • GBIO $0.34
  • DRIO $0.50
  • Resistance Level
  • GBIO $0.40
  • DRIO $0.76
  • Average True Range (ATR)
  • GBIO 0.05
  • DRIO 0.07
  • MACD
  • GBIO 0.01
  • DRIO 0.02
  • Stochastic Oscillator
  • GBIO 61.29
  • DRIO 95.04

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About DRIO DarioHealth Corp.

DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.

Share on Social Networks: